Is Hand, Foot, and Mouth Disease Dangerous During Pregnancy?

Hand, foot, and mouth disease during pregnancy is usually a mild, self-limiting illness for the mother, but it carries rare risks to the fetus and newborn that depend heavily on the timing of infection and the specific virus strain involved. Most pregnant women who catch the disease recover within a week or two with no complications for themselves or their baby. The concern is that certain enteroviruses responsible for the illness can, in uncommon cases, cross the placenta or be transmitted around the time of delivery, potentially causing miscarriage, stillbirth, or serious neonatal infection. The evidence base on this topic is surprisingly thin, built mostly on case reports and small case series rather than large studies, which makes definitive risk estimates difficult.

What HFMD Looks Like in Pregnant Women

HFMD is caused by a group of enteroviruses, most commonly Coxsackievirus A16 and Enterovirus 71 (EV71). The hallmark symptoms are fever, painful mouth sores, and a blistering rash on the hands, feet, and sometimes the buttocks or genitalia.¹ Adults typically pick it up through fecal-oral contact in household settings, which is why parents of young children are the adults most likely to get it.

Pregnant women are thought to be somewhat more susceptible to infection, particularly in the later stages of pregnancy when the immune system is naturally suppressed to prevent rejection of the fetus.² In a seven-year study from Tuscany that tracked 128 pregnant women exposed to HFMD, about 41% developed symptoms. Of those symptomatic women, roughly 62% developed the classic hand-foot-mouth blisters, about 23% had blisters limited to the palms and soles, and about 15% had only oral sores.³ In other words, more than half of exposed pregnant women showed no symptoms at all, and many of those who did had relatively limited disease.

For the mother herself, the illness is almost always uncomplicated. The fever and rash resolve on their own, and serious maternal illness from HFMD is extraordinarily rare. The real question is what happens on the other side of the placenta.

Can the Virus Cross the Placenta?

One of the central questions about any infection during pregnancy is whether the pathogen can reach the fetus. For the enteroviruses behind HFMD, the answer is: not easily, but it does happen. Laboratory experiments using a perfused placenta model found that Coxsackievirus B3 and ECHO-11 virus did not cross the placental barrier even when very high viral loads were introduced on the maternal side, leading researchers to conclude that transplacental passage does not occur readily and that most babies of infected mothers will be unharmed.⁴

That said, rare case reports prove it can happen. In one well-documented case, a 28-year-old woman at 13 weeks of pregnancy developed HFMD shortly after her two-year-old son had the illness. She miscarried a week later, and Coxsackievirus A16 was isolated from both the placental tissue and the fetus’s organs, confirming that the virus had crossed the placenta and was directly associated with the fetal loss.⁵ Another case report documented Coxsackievirus A16 infecting the placenta and causing massive fibrin deposits, leading to fetal death at 36 weeks.⁶

When researchers have examined placentas from enterovirus-positive pregnancies, they find a pattern of inflammation: clusters of immune cells called histiocytes between the villi, along with areas where the trophoblast cells that line the placenta have died off. These findings are consistent with an acute blood-borne infection of the placenta.⁷ ⁸ Some pathologists believe enterovirus placentitis may be underdiagnosed because clinicians do not routinely test for it.

So the placenta does a reasonable job as a barrier, but it is not impenetrable. The virus gets through rarely, but when it does, the consequences can be severe.

Risks in Early Pregnancy

Infection during the first trimester is the scenario that worries clinicians most, even though the evidence is sparse. Coxsackievirus B infections have been linked to an increased rate of early spontaneous abortion.⁹ The case from the BMJ where Coxsackievirus A16 was isolated from fetal tissue after a 13-week miscarriage is one of the clearest pieces of evidence for a direct link between the HFMD-causing viruses and early pregnancy loss.⁵

A rare complication sometimes mentioned in the literature is fetal myocarditis, where the virus infects the fetal heart muscle. This has been reported with Coxsackievirus B rather than the A strains, and it remains an extremely uncommon event.⁹ Echoviruses, another enterovirus group that can cause HFMD-like illness, do not appear to damage the fetus based on available data.

The Tuscan study mentioned earlier reported three miscarriages among 128 tracked women, along with a few cases of fetal or neonatal anomalies, but the authors themselves cautioned that the data on fetal outcomes are “not conclusive.”³ That caveat is important. We are dealing with case reports and small series, not controlled studies. The absolute risk of miscarriage attributable to HFMD is unknown, and it is likely very low relative to the background miscarriage rate.

Risks Near Delivery

When a mother is actively infected with an enterovirus around the time of delivery, the baby can be exposed during passage through the birth canal or through close contact immediately after birth. This peripartum transmission is thought to be the more common route by which newborns acquire HFMD, compared to the rarer transplacental route.²

The concern here is that newborns have immature immune systems and limited ability to fight enteroviruses on their own. Severe neonatal infections, while rare, can include respiratory failure and central nervous system complications.⁶ One documented neonatal case involved a baby who developed brainstem encephalitis and pulmonary edema after exposure to EV71. The infant’s course was dramatic, with seizures, coma, and loss of spontaneous breathing, but ultimately she recovered fully.¹⁰ That case report highlights two things simultaneously: neonatal HFMD can be frightening, and even severe cases can resolve completely.

Not all neonatal cases are that dramatic. A study from Shanghai looking at newborns infected with Coxsackievirus A6 found that none of the infected neonates developed fever, nail shedding, or serious complications. They had all caught the virus from family members, usually older siblings, and their symptoms cleared within about a week with no lasting effects.¹¹ The severity of neonatal disease depends heavily on which virus strain is involved.

Why the Virus Strain Matters

Not all enteroviruses that cause HFMD are created equal, and the strain distinction is particularly relevant for pregnant women wondering how worried to be. Coxsackievirus A16 and Coxsackievirus A6 tend to cause milder disease. EV71 is the outlier. In a large retrospective study comparing the two main strains, neurological complications occurred in about 63% of EV71-infected patients compared to roughly 5% of those infected with Coxsackievirus A16. All patients with Coxsackievirus A16 recovered fully, while about 4% of those with EV71 had lasting neurological problems at discharge, and about 3% of EV71 cases died.¹²

That study looked at children, not pregnant women or newborns specifically, but the pattern holds broadly: EV71 is a more aggressive virus that has a predilection for the nervous system. When researchers worry about serious fetal or neonatal outcomes from maternal HFMD, EV71 is the strain they are most concerned about. In regions of the world where EV71 circulates heavily, particularly parts of East and Southeast Asia, HFMD outbreaks tend to produce more severe cases overall.

For a pregnant woman in a Western country where Coxsackievirus A strains dominate, the risk profile is generally more reassuring than it would be in a setting with heavy EV71 transmission. That said, strain identification is not typically done in routine clinical practice. Your doctor may not know which specific enterovirus you have unless specialized testing is ordered.

Treatment During Pregnancy

There is no antiviral drug that works against the enteroviruses responsible for HFMD. Treatment is supportive: managing fever, staying hydrated, and relieving pain from mouth sores. For pregnant women, this means acetaminophen for fever and pain, cold fluids or ice chips for mouth ulcers, and rest.

In one documented case of a pregnant woman hospitalized with HFMD, the treatment included antibiotics to prevent secondary bacterial infection of the skin lesions, analgesics, and steroids, with the patient supervised for five days. Her condition improved within four days, and she experienced no complications like difficulty swallowing, disorientation, or preterm labor.² Antibiotics do not treat the virus itself; they are only relevant if there is concern about bacterial superinfection of open skin lesions.

The key clinical priority during pregnancy is monitoring for any signs of complications: persistent high fever, severe headache, confusion, or any neurological symptoms in the mother. Fetal monitoring may also be warranted, particularly if the infection occurs in the third trimester close to the due date. If you develop HFMD while pregnant, the most practical step is to contact your obstetrician early so they can decide on the level of monitoring appropriate for your stage of pregnancy.

Prevention When You Have a Toddler at Home

The most common way pregnant women catch HFMD is from their own young children. The virus spreads through saliva, nasal mucus, fluid from blisters, and stool, which makes the diaper-changing and face-wiping realities of parenting a toddler the primary risk factor. The Tuscan study specifically noted that household exposure was the dominant route.³

Complete avoidance is unrealistic when you are the primary caregiver of a sick child, but basic hygiene measures reduce transmission:

Hand washing: Wash thoroughly after diaper changes, after wiping your child’s nose or mouth, and before eating. Soap and water for at least 20 seconds is more effective than hand sanitizer against enteroviruses.
Avoid sharing: Do not share utensils, cups, or towels with the sick child. This is easier said than done with a clingy toddler, but it matters.
Surface cleaning: Disinfect commonly touched surfaces, toys, and changing areas. Enteroviruses can survive on surfaces for hours.
Blister fluid: Avoid direct contact with blister fluid, which carries a high viral load. The Tuscan study found that direct enterovirus detection from vesicle fluid was positive in nearly 69% of tested samples.

Despite best efforts, many parents catch HFMD from their children anyway. The virus is highly contagious, shedding begins before symptoms appear, and the fecal shedding can continue for weeks after the rash clears. If you are pregnant and your child comes home from daycare with the characteristic rash, the exposure has likely already happened.

Maternal Antibodies and Infant Protection

One reassuring piece of the puzzle is that mothers who have been exposed to enteroviruses before or during pregnancy typically develop antibodies that cross the placenta and offer temporary protection to the newborn. A Chinese seroepidemiological study found that about 85% of women near delivery had neutralizing antibodies against EV71, and about 89% had antibodies against Coxsackievirus A16.¹³ These high rates reflect how common enterovirus exposure is over a lifetime.

Those maternal antibodies transfer to the baby and provide a window of protection during the first months of life. At two months of age, about 58% of infants still had detectable EV71 antibodies and about 40% had Coxsackievirus A16 antibodies. By seven months, the rates dropped to roughly 41% and 26%, respectively. Infants who were seronegative for EV71 antibodies at two months had a significantly higher incidence of HFMD compared to infants who still carried maternal antibodies.¹³ This means maternal antibodies do provide real, measurable protection to newborns, but the protection is temporary and varies by virus type.

The flip side is that babies born to mothers who lack enterovirus antibodies, perhaps because the mother was never exposed to a particular strain, enter the world without that passive immunity. This is partly why neonatal HFMD, though rare, tends to be more severe than HFMD in older infants: the youngest babies may lack any immunological head start against the virus.

The Vaccine Landscape

As of now, no HFMD vaccine is available for pregnant women. Inactivated EV71 vaccines have been licensed in China for use in young children, but they are not approved for adults or pregnant women, and they only target EV71, leaving the Coxsackievirus A strains uncovered. Research into broader vaccines and newer approaches continues. Experimental work with a recombinant viral protein (VP1) from EV71 has shown that vaccinated female mice pass protective antibodies to their offspring, and that these antibodies can neutralize the virus.¹⁴ ¹⁵

There is an interesting wrinkle in this research: while maternal antibodies protect newborns in the short term, they also interfere with the newborn’s ability to mount its own immune response when later vaccinated. In the mouse model, offspring born to VP1-immunized mothers had trouble generating their own antibody-producing cells when they received the vaccine themselves.¹⁵ This is a well-known phenomenon in vaccinology and would need to be worked around before a maternal vaccination strategy could be implemented for HFMD. For now, the concept of vaccinating pregnant women against HFMD to protect their newborns remains firmly in the research phase.

What the Animal Data Add

Much of what researchers know about how enteroviruses affect pregnancy comes from animal models, since controlled studies in pregnant humans are obviously impossible. Mouse studies using Theiler’s murine encephalomyelitis virus (a related enterovirus) found that rates of fetal abnormalities and placental infection in infected mothers exceeded the rate of direct fetal viral infection. This suggests the virus can harm pregnancy even without infecting the fetus directly, possibly by damaging the placenta and compromising its function.¹⁶

The placental perfusion experiments mentioned earlier, which found that Coxsackievirus B3 did not cross the placenta easily, used an isolated laboratory model that may not fully replicate the conditions inside a living pregnancy. Factors like inflammation, immune responses, and the health of the placenta itself could affect how well the barrier holds in a real infection.⁴ The gap between what the lab models show and what the scattered human case reports describe is one of the reasons this field remains so uncertain.

Why Coxsackievirus Infections Are Easy to Miss

One factor that complicates the picture is that many Coxsackievirus infections in pregnant women produce no symptoms at all. A significant fraction of exposed women never develop the characteristic rash or mouth sores, meaning they would never know they had been infected unless someone tested their blood for antibodies. In the Tuscan cohort, 59% of the exposed pregnant women were asymptomatic.³ This matters because it means that any adverse pregnancy outcome linked to enterovirus exposure could easily be attributed to something else if the infection was never detected.

Routine prenatal screening does not include testing for enteroviruses. If a woman miscarries at 12 weeks and never had a rash, no one tests for Coxsackievirus. This underdetection is part of why pathologists have argued that enterovirus placentitis is underrecognized as a cause of placental pathology.⁷ The true frequency of enterovirus-related pregnancy complications may be higher than the case-report literature suggests, though it is almost certainly still low in absolute terms. Enteroviruses are extremely common; millions of infections occur every year, and the vast majority cause no documented pregnancy problems. The denominator is enormous, even if the numerator is undercounted.